Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer

Dmitri Pchejetski, Torsten Böhler, Justin Stebbing, Jonathan Waxman

Research output: Contribution to journalArticlepeer-review

46 Citations (Scopus)


Sphingosine kinase 1 (SK1) is a lipid enzyme with oncogenic properties that converts the proapoptotic lipid sphingosine into the antiapoptotic lipid sphingosine-1-phosphate, which activates the signal transduction pathways that lead to cell proliferation, migration, activation of the inflammatory response and impairment of apoptosis. Compelling evidence suggests that SK1 activation contributes to cancer progression leading to increased oncogenic transformation, tumor growth, resistance to therapies, tumor neovascularization and metastatic spread. High levels of SK1 expression or activity have been associated with poor prognosis in several cancers, including those of the prostate. Recent studies using prostate cancer cell and mouse models demonstrate a significant potential for SK1-targeting therapies to synergize with the effects of docetaxel chemotherapy and radiotherapy. However, until recently the absence of clinically applicable SK1 inhibitors has limited the translation of these findings into patients. With the recent discovery that clinically approved drug fingolimod has SK1-inhibiting properties, SK1 has gained significant attention from both clinicians and the pharmaceutical industry and it is hoped that trials of newly developed SK1 inhibitors might follow soon.
Original languageEnglish
Pages (from-to)569-578
Number of pages10
JournalNature Reviews Urology
Issue number10
Publication statusPublished - Oct 2011


  • Animals
  • Disease Models, Animal
  • Humans
  • Male
  • Mice
  • Phosphotransferases (Alcohol Group Acceptor)
  • Propylene Glycols
  • Prostatic Neoplasms
  • Signal Transduction
  • Sphingosine

Cite this